Advancing Cancer Therapy with Present and Emerging Immuno-Oncology Approaches

CTLA-4 and PD-1 Pathways

(2016) Elizabeth I. Buchbinder et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Oncolytic virus therapy: A new era of cancer treatment at dawn

(2016) Hiroshi Fukuhara et al.   CANCER SCIENCE

Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma

(2016) Nicole C. Smits et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

(2016) F. Stephen Hodi et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical Profile of Cyclooxygenase-2 Inhibitors in Treating Non-Small Cell Lung Cancer: A Meta-Analysis of Nine Randomized Clinical Trials

(2016) Yuan Yuan Zhou et al.   PLoS One

Oncolytic viruses as immunotherapy: progress and remaining challenges

(2016) Laure Aurelian   OncoTargets and Therapy

Clinical utility of nivolumab in the treatment of advanced melanoma

(2016) Richard D. Carvajal et al.   Therapeutics and Clinical Risk Management

Moving oncolytic viruses into the clinic: clinical-grade production, purification, and characterization of diverse oncolytic viruses

(2016) Guy Ungerechts et al.   Molecular Therapy-Methods & Clinical Development

Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC)

(2015) Xiao-jun Lin et al.   BMC CANCER

Tadalafil Augments Tumor Specific Immunity in Patients with Head and Neck Squamous Cell Carcinoma

(2015) J. A. Califano et al.   CLINICAL CANCER RESEARCH

Blinatumomab for the Treatment of Philadelphia Chromosome-Negative, Precursor B-cell Acute Lymphoblastic Leukemia

(2015) O. Wolach et al.   CLINICAL CANCER RESEARCH

Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases

(2015) S. C. Katz et al.   CLINICAL CANCER RESEARCH

Utilizing the BiTE (bispecific T-cell engager) platform for immunotherapy of cancer

(2015) Julia Stieglmaier et al.   EXPERT OPINION ON BIOLOGICAL THERAPY

Imiquimod - Its role in the treatment of cutaneous malignancies

(2015) AdityaKumar Bubna   INDIAN JOURNAL OF PHARMACOLOGY

Solitomab, an EpCAM/CD3 bispecific antibody construct (BiTE®), is highly active against primary uterine and ovarian carcinosarcoma cell lines in vitro

(2015) Francesca Ferrari et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Big opportunities for small molecules in immuno-oncology

(2015) Jerry L. Adams et al.   NATURE REVIEWS DRUG DISCOVERY

Adoptive cell transfer as personalized immunotherapy for human cancer

(2015) S. A. Rosenberg et al.   SCIENCE

T-cell-based Immunotherapy: Adoptive Cell Transfer and Checkpoint Inhibition

(2015) R. Houot et al.   Cancer Immunology Research

Trial Watch: Adoptive cell transfer for oncological indications

(2015) Fernando Aranda et al.   OncoImmunology

Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy

(2015) Kristina Iribarren et al.   OncoImmunology

Antitumor activity and safety of combination therapy with the Toll-like receptor 9 agonist IMO-2055, erlotinib, and bevacizumab in advanced or metastatic non-small cell lung cancer patients who have progressed following chemotherapy

(2014) David A. Smith et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Cancer vaccine adjuvants – recent clinical progress and future perspectives

(2014) Abid H. Banday et al.   IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY

Maintenance treatment with the immunomodulator MGN1703, a Toll-like receptor 9 (TLR9) agonist, in patients with metastatic colorectal carcinoma and disease control after chemotherapy: a randomised, double-blind, placebo-controlled trial

(2014) Hans-Joachim Schmoll et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

What's fueling the biotech engine—2012 to 2013

(2014) Saurabh (Rob) Aggarwal   NATURE BIOTECHNOLOGY

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma

(2013) Jedd D. Wolchok et al.   Annals of the New York Academy of Sciences

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors

(2013) Shahneen K. Sandhu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

(2013) Richard A. Morgan et al.   JOURNAL OF IMMUNOTHERAPY

Cancer Immunotherapy

(2013) J. Couzin-Frankel   SCIENCE

Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol

(2012) Karsten Geletneky et al.   BMC CANCER

Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2

(2012) Tadashi Yokosuka et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

(2012) Anna Maria Di Giacomo et al.   LANCET ONCOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Activator protein 1 suppresses antitumor T-cell function via the induction of programmed death 1

(2012) G. Xiao et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation

(2012) N. Patsoukis et al.   Science Signaling

Pre-emptive plerixafor injection increases blood neutrophil, lymphocyte and monocyte counts in addition to CD34+ counts in patients with non-Hodgkin lymphoma mobilizing poorly with chemotherapy plus G-CSF: Potential implications for apheresis and graft composition

(2012) V. Varmavuo et al.   TRANSFUSION AND APHERESIS SCIENCE

Targeting the tumor mutanome for personalized vaccination therapy

(2012) Sebastian Kreiter et al.   OncoImmunology

TG4010

(2012) Jean-Marc Limacher et al.   OncoImmunology

Clinical trial results of the HER-2/neu(E75) vaccine to prevent breast cancer recurrence in high-risk patients

(2011) Elizabeth A. Mittendorf et al.   CANCER

Hallmarks of Cancer: The Next Generation

(2011) Douglas Hanahan et al.   CELL

Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy

(2011) S. A. Rosenberg et al.   CLINICAL CANCER RESEARCH

Tumor Regression in Patients With Metastatic Synovial Cell Sarcoma and Melanoma Using Genetically Engineered Lymphocytes Reactive With NY-ESO-1

(2011) Paul F. Robbins et al.   JOURNAL OF CLINICAL ONCOLOGY

OPTIM trial: a Phase III trial of an oncolytic herpes virus encoding GM-CSF for unresectable stage III or IV melanoma

(2010) Howard L Kaufman et al.   Future Oncology

Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF

(2010) Michael Quigley et al.   NATURE MEDICINE

Oncolytic Viruses for Cancer Therapy: Overcoming the Obstacles

(2010) Han Hsi Wong et al.   Viruses-Basel

Prostvac-VF: a vector-based vaccine targeting PSA in prostate cancer

(2009) Ravi A Madan et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

CD28 and CTLA-4 coreceptor expression and signal transduction

(2009) Christopher E. Rudd et al.   IMMUNOLOGICAL REVIEWS

Cyclooxygenase-2 Inhibitors in Colorectal Cancer Prevention: Point

(2008) N. Arber   CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION

Suppression of Tumor Formation by a Cyclooxygenase-2 Inhibitor and a Peroxisome Proliferator-Activated Receptor   Agonist in an In vivo Mouse Model of Spontaneous Breast Cancer

(2008) A. Mustafa et al.   CLINICAL CANCER RESEARCH

Cyclooxygenase-2 Expression Is an Independent Predictor of Poor Prognosis in Colon Cancer

(2008) S. Ogino et al.   CLINICAL CANCER RESEARCH